Fiasp® approved in Europe for the management of diabetes in adolescents and chil ... Read more


Novo Nordisk A/S: Securities lawsuit filed in Denmark against Novo Nordisk ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more


Novo Nordisk A/S: Securities lawsuit filed in Denmark against Novo Nordisk ... Read more


Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more


Novo Nordisk's operating profit increased by 12% in Danish kroner and by 6% at c ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
Press material is intended for media.


Novo Nordisk Media

production Denmark

Financial results for the first six months of 2019

Novo Nordisk's operating profit increased by 12% in DKK and 6% at CER

Bagsværd 9 August - CEO Lars Fruergaard Jørgensen about the results: "We're pleased with the sales growth in the first half of 2019, which is driven by all regions in International Operations. The launch of Ozempic® is expanding the GLP-1 market, and we're encouraged by the positive market reception in both North America and Europe. With the initiation of four major late-stage clinical trials, we continue to investigate the clinical benefits of semaglutide across multiple indications. The solid financial performance in the first half of 2019 has enabled us to raise our outlook for the full-year."

Read all the details in the financial report


production Denmark

The technology behind tablets

What if medicines injected by millions could be delivered in tablets? After almost 100 years of delivering injectable therapies, Novo Nordisk’s R&D team is finding answers to this enduring question. Chief Science Officer Mads Krogsgaard Thomsen is leading the way and he reflects on the magnitude of the scientific challenge and the progress made in his laboratories.

Read Mads' reflections


Circular for zero

Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact  

Novo Nordisk intends to achieve the target to use only renewable electricity in its global production facilities by 2020. The announcement on 30 April followed a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.

Read more about Circular for Zero and download the full press release on the environmental ambitions 


Towards a cure

When Becky Furuta was told her cycling career was over due to her diabetes, she defied doctors' orders to rise to the top of her profession.

Read the story about Beckypro-cyclist at Team Novo Nordisk, or listen to her story in the podcast

Subscribe to our perspectives 


Red Cross and Novo Nordisk in ground-breaking partnership to tackle chronic care in humanitarian crises

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership



16SeptemberBarcelona, Spain

When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years. 

Watch the documentary, 'Safely in the Rainbow', on YouTube

Financial results 2019

9 August - first half 

1 November - third quarter 


Novo Nordisk in brief

Defeat NCDs

Zeana Massoud Said has type 1 diabetes. Zeana lives in Tanzania

The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.

Read more details in the press release